Latest clinical study may shut door on secretin as autism drug

01/6/2004 | NYTimes.com

Repligen announced its latest clinical trial of the drug secretin has failed to prove the efficacy of using it to treat autism. The decision, following the largest and most definitive trial of the drug, casts doubt on whether secretin will ever become a treatment for the childhood disease.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ